Category: Vaccines

  • Community Profile Reports now have vaccination data

    Community Profile Reports now have vaccination data

    You can now get vaccination numbers for U.S. states, counties, and metropolitan areas in an easily downloadable format: the Community Profile Reports published daily by the Department of Health and Human Services (HHS). These reports are basically the HHS’s one-stop shop for COVID-19 data, including information on cases, deaths, PCR tests, hospitalizations—and now, vaccines. (Read more about the reports here.)

    For counties and metro areas, the reports just include numbers and percentages of people who have been fully vaccinated, reported for the overall population and the regions’ seniors (age 65+). For states, the reports include more comprehensive information that matches the data available at the CDC’s COVID Data Tracker.

    I visualized the county-level data, including both the overall and 65+ rates. I think this chart demonstrates how valuable it is for the public to have easy access to these data: you can see much more specific patterns reflecting which communities are ahead on vaccination and which still need to catch up.

    A COVID Tracking Project friend alerted me to this data news last Monday, April 19. When I dug back into the past couple weeks of Community Profile Reports, however, I found that the HHS started including vaccination data in these reports one week earlier, on April 12. As seems to be common for federal data updates, the new information wasn’t announced in press briefings or other standard lines of communication.

    Next, I would love to see the CDC make more granular demographic data available so that we can analyze these patterns with an equity lens. State-level or county-level vaccination rates by race and ethnicity would be huge.

    As a reminder, you can find the CDD’s annotations on all major U.S. national and state vaccine data sources here.

    More vaccine coverage

    • Sources and updates, November 12
      Sources and updates for the week of November 12 include new vaccination data, a rapid test receiving FDA approval, treatment guidelines, and more.
    • How is the CDC tracking the latest round of COVID-19 vaccines?
      Following the end of the federal public health emergency in May, the CDC has lost its authority to collect vaccination data from all state and local health agencies that keep immunization records. As a result, the CDC is no longer providing comprehensive vaccination numbers on its COVID-19 dashboards. But we still have some information about this year’s vaccination campaign, thanks to continued CDC efforts as well as reporting by other health agencies and research organizations.
    • Sources and updates, October 8
      Sources and updates for the week of October 8 include new papers about booster shot uptake, at-home tests, and Long COVID symptoms.
    • COVID source shout-out: Novavax’s booster is now available
      This week, the FDA authorized Novavax’s updated COVID-19 vaccine. Here’s why some people are excited to get Novavax’s vaccine this fall, as opposed to Pfizer’s or Moderna’s.
  • How to talk about breakthrough cases

    How to talk about breakthrough cases

    This week, The Hill posted an article with a rather misleading headline: “CDC finds less than 1 percent of fully vaccinated people got COVID-19.” If you actually click into the piece, you’ll find that the precise number is less than 0.008%. Less than 0.0005% have been hospitalized and less than 0.0001% have died.

    This headline reflects a common issue with vaccine reporting that I’ve seen in the past few weeks. A lot of journalists, especially those who aren’t familiar with the science/health beat, may be inclined to publish news of breakthrough cases as surprising or monumental. In fact, these cases—referring to a COVID-19 infection that occurs after someone has been fully vaccinated—are entirely normal, yet incredibly rare.

    No vaccine is perfect. Even the Pfizer and Moderna vaccines, which both demonstrated 95% efficacy in their late-stage clinical trials and over 90% effectiveness in the real world, are not perfect. Scientists still expect a few COVID-19 infections to slip through the immune system defenses built up by these vaccines and cause illness in a small number of patients.

    And it really is a small number: 129 million Americans have received at least one dose of a COVID-19 vaccine as of yesterday, per the CDC, and 82 million have been fully vaccinated. The agency has only documented 5,800 breakthrough cases. Less than 0.008% of those people who have been fully vaccinated. That’s the equivalent of one-quarter of a seat in Queens’ Citi Field baseball stadium (which seats about 42,000).

    So, if you’re a journalist reporting on this issue—whether it’s nationally or in your community—it’s important to stress that denominator. 82 million fully vaccinated, 5,800 breakthrough cases. Emphasizing the difference in magnitude between these numbers can show readers that, while they should still maintain some caution after getting vaccinated, the vaccines are overwhelmingly safe and effective.

    Small as the breakthrough case numbers are, though, it is important that we still talk about them. A new article by ProPublica’s Caroline Chen discusses how a failure to collect data on breakthrough cases is making it harder for COVID-19 researchers to understand what causes them. Specifically: we should be sequencing the genomes of the coronavirus strains that caused these cases, and by and large, we aren’t.

    Chen describes how many state health departments aren’t getting breakthrough case samples to sequence, whether that’s due to testing labs failing to store the test samples or cases being identified through rapid tests, which do not have established pipelines. Plus, in some cases, we aren’t even recording whether the patients went to the hospital or died—key data points in the U.S.’s continued vaccine monitoring.

    I definitely recommend you read the full piece, but here’s a section that will give you the big idea:

    In many instances, patients’ samples are not sequenced to find out if a variant might have been involved; some labs are throwing out test samples before an analysis can be done; hospitals and clinics aren’t always collecting new samples to analyze them. That means that for so many people, nobody will ever know if a variant was involved, leaving public health officials without data to be able to examine the extent to which variants are contributing to breakthrough cases.

    “It’s alarming that we can’t sequence more of the virus than we’re able to now — that’s something we need to resolve,” said Brian Castrucci, chief executive officer at the de Beaumont Foundation, a health philanthropy. “The more we know, the better we can react. We want to know the information so that we can make the right policy and health decisions.”

    While the CDC has an info page on breakthrough cases, no data on these cases are available on the agency’s COVID-19 dashboard. Reporters need to walk a delicate line on this issue: pursue the data, but report it in a careful, conscientious way that appropriately puts the tiny breakthrough case numbers in context.

    More vaccine news

    • Sources and updates, November 12
      Sources and updates for the week of November 12 include new vaccination data, a rapid test receiving FDA approval, treatment guidelines, and more.
    • How is the CDC tracking the latest round of COVID-19 vaccines?
      Following the end of the federal public health emergency in May, the CDC has lost its authority to collect vaccination data from all state and local health agencies that keep immunization records. As a result, the CDC is no longer providing comprehensive vaccination numbers on its COVID-19 dashboards. But we still have some information about this year’s vaccination campaign, thanks to continued CDC efforts as well as reporting by other health agencies and research organizations.
    • Sources and updates, October 8
      Sources and updates for the week of October 8 include new papers about booster shot uptake, at-home tests, and Long COVID symptoms.
    • COVID source shout-out: Novavax’s booster is now available
      This week, the FDA authorized Novavax’s updated COVID-19 vaccine. Here’s why some people are excited to get Novavax’s vaccine this fall, as opposed to Pfizer’s or Moderna’s.
  • Did you know that you, a plebeian, can search through VAERS?

    Did you know that you, a plebeian, can search through VAERS?

    You’ve probably heard about the Johnson & Johnson debacle by now. (Here’s an explainer on NYT’s The Daily and another one with more scientific background from Roxanne Khamsi at The Atlantic if you’re still confused.)

    If you attended or read about the April 14 emergency ACIP (Advisory Committee on Immunization Practices) meeting discussing the pause, you probably heard “VAERS” a lot. VAERS stands for “Vaccine Adverse Event Reporting System.” It’s used as a “national early warning system to detect possible safety problems in U.S.-licensed vaccines,” it’s been around for much longer than the COVID-19 vaccines or even COVID-19, and it’s how regulators are examining the data about possible complications related to the Johnson & Johnson COVID-19 vaccine. And as the cherry on top, the data is open to the public through the WONDER search engine. So what’s there?

    The search procedure is VERY customizable, and there’s even a video teaching you how to do it. You can narrow your search by symptoms, vaccine type, vaccine products, date that the event was reported, and more. For my cursory search, I, like a lot of people, was curious about the results for the Johnson & Johnson COVID-19 vaccine, so I just narrowed my search to “COVID-19 Vaccine Janssen.” 

    Here are my results, sorted by most common symptoms:

    These are the most common results, but the list keeps going after that with rarer side effects as you go down. It quickly became clear that this is not a perfect system, with some slightly nonsensical reports and strange distinctions. I was certainly left wondering how “SARS-COV-2 test negative” ended up as an adverse effect. (Seems like that’s what you want? Either way, there were 59 of these reported. Good for those 59 people—or that one person with a very sore nose.)

    Also notable were “Feeling abnormal” (213 reports), “Irritability” (10 reports) and my personal favorite, “No adverse event” (58 reports). It’s fairly obvious that not all of these adverse events were directly caused by the vaccine. Indeed, while the list can be fun to poke through and somewhat illuminating in what keeps popping up (headache, chills, pain, pyrexia/fever), finding the most common symptoms seems to be its main use.

    J&J distribution is paused right now because there were 6 cases of cerebral venous sinus thrombosis (CVST) combined with low platelets in a group where that is not common, and symptoms manifested between 6 and 13 days after vaccination. However, you can’t see that from this dataset. It doesn’t even seem like this dataset is fully updated—right now, there’s only one case of CVST recorded. (It was last updated on April 10.) The dataset also doesn’t actually say when the person got vaccinated and when the event was reported—just frequency. 

    In the April 14 emergency ACIP meeting, Dr. Tom Shimabukuro of the CDC COVID-19 Vaccine Task Force cited the 6 reports as of April 12, so it looks like the public dataset hasn’t been updated while the people actually making decisions are working with updated data. It doesn’t mean that this dataset isn’t useful, it just means that one should act with caution before using it to draw any conclusions. 

    The CDC clearly agrees with me, as they make you check a box stating that you’ve read the disclaimers like “reports may include incomplete, inaccurate, coincidental and unverified information” and “the number of reports alone cannot be interpreted or used to reach conclusions about the existence, severity, frequency, or rates of problems associated with vaccines” before they show you the goods in WONDER.

    There’s also a 17-page “VAERS Data Use Guide” which of course I found when I was almost done writing this up. Despite the limitations of the actual public dataset, I was extremely impressed by how much guidance that’s provided. I haven’t had my hand held this much while sifting through data in ages (I was very much on my own while going through the Global.Health database) and it really shows how much they want this data to be used with care. So I give serious props for solid and effective guidance on how to communicate this data—I just wish there was more data to communicate. 

    But WONDER isn’t the only way to sift through all the data. You can also download CSV files of every event reported (supposedly) back until 1990. That’d be a bit much for one post, but next week we might see what’s there.

    More vaccine news

    • Sources and updates, November 12
      Sources and updates for the week of November 12 include new vaccination data, a rapid test receiving FDA approval, treatment guidelines, and more.
    • How is the CDC tracking the latest round of COVID-19 vaccines?
      Following the end of the federal public health emergency in May, the CDC has lost its authority to collect vaccination data from all state and local health agencies that keep immunization records. As a result, the CDC is no longer providing comprehensive vaccination numbers on its COVID-19 dashboards. But we still have some information about this year’s vaccination campaign, thanks to continued CDC efforts as well as reporting by other health agencies and research organizations.
    • Sources and updates, October 8
      Sources and updates for the week of October 8 include new papers about booster shot uptake, at-home tests, and Long COVID symptoms.
    • COVID source shout-out: Novavax’s booster is now available
      This week, the FDA authorized Novavax’s updated COVID-19 vaccine. Here’s why some people are excited to get Novavax’s vaccine this fall, as opposed to Pfizer’s or Moderna’s.
  • there might be a link between the Oxford-AstraZeneca vaccine and those blood clots after all

    AstraZeneca still isn’t out of the woods yet. In fact, the woods seem to be just getting deeper, and now I’m fairly certain it’s not me jinxing things.

    Last time we covered AstraZeneca’s blood clot woes, the European Medicines Agency (EMA) had said in a March 18 press conference that “[t]he committee… concluded that the vaccine is not associated with an increase in the overall risk of thromboembolic events or blood clots.” (Thrombosis just means blood clotting.)

    But this week, authorities had enough data to posit a possible connection between blood clots known as cerebral venous sinus thrombosis (CVST) and the Oxford-AstraZeneca vaccine. The EMA has now advised, as of April 7, that “that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).” They are still recommending its use given the gravity of the COVID-19 pandemic, but it’s another blow to the vaccine that held much of the world’s hopes in inoculating the entire population. A mechanism by which the vaccine is causing these thromboses has not been discovered.

    As of April 4, there had been 222 cases of abnormal thromboses in Britain and the European Economic Area after receiving the Oxford-AstraZeneca vaccine, according to the New York Times. This is out of about 34 million people being vaccinated, and they estimated that the frequency was about 1 in 100,000. In total, the EMA committee looked at “62 cases of cerebral venous sinus thrombosis and 24 cases of splanchnic vein thrombosis reported in the EU drug safety database (EudraVigilance) as of 22 March 2021, 18 of which were fatal.” 

    This made us wonder how this compares to the early reports of anaphylaxis (serious allergic reactions) in recipients of the Pfizer-BioNTech and Moderna mRNA vaccines. According to an early report from the CDC, there were 21 cases out of 1,893,360 Pfizer-BioNTech first doses, for a frequency of 11.1 cases per million, or about 1 in 90,000. A later JAMA paper reported updated rates of about 4.7 cases per million doses for Pfizer-BioNTech and 2.5 cases per million for Moderna. To make the scales easier to compare, this works out to about 1 in 213,000 and 1 in 400,000, respectively.

    Comparing 1 in 213,000 and 1 in 400,000 cases of anaphylaxis to 1 in 100,000 cases of serious blood clots, it makes sense why some authorities are starting to hit the brakes on the AstraZeneca vaccine. No deaths were reported with the anaphylaxis reactions, but out of the sample of thromboses that the EMA examined, 18 people died. Not only are the numbers worse, but anaphylaxis reactions can also be easier to prepare for. In that early CDC report, 71% of anaphylaxis reactions occurred within 15 minutes of vaccination. For this reason, vaccine clinics monitor you for about 15 minutes (mine sure did). That’s harder to do with blood clots, which take much longer than 15 minutes to manifest and can’t be treated with an EpiPen on the spot. 

    Again, this is definitely a blow for what’s still a very effective vaccine. But taking these precautions is how faith in vaccines is earned and kept. We hold vaccines to a high standard for a reason.

    More vaccine coverage

    • Sources and updates, November 12
      Sources and updates for the week of November 12 include new vaccination data, a rapid test receiving FDA approval, treatment guidelines, and more.
    • How is the CDC tracking the latest round of COVID-19 vaccines?
      Following the end of the federal public health emergency in May, the CDC has lost its authority to collect vaccination data from all state and local health agencies that keep immunization records. As a result, the CDC is no longer providing comprehensive vaccination numbers on its COVID-19 dashboards. But we still have some information about this year’s vaccination campaign, thanks to continued CDC efforts as well as reporting by other health agencies and research organizations.
    • Sources and updates, October 8
      Sources and updates for the week of October 8 include new papers about booster shot uptake, at-home tests, and Long COVID symptoms.
    • COVID source shout-out: Novavax’s booster is now available
      This week, the FDA authorized Novavax’s updated COVID-19 vaccine. Here’s why some people are excited to get Novavax’s vaccine this fall, as opposed to Pfizer’s or Moderna’s.
  • CDC says 80% of teachers and childcare workers are vaccinated, fails to provide more specifics

    CDC says 80% of teachers and childcare workers are vaccinated, fails to provide more specifics

    This past Tuesday, April 6, the Centers for Disease Control and Prevention put out a press release that I found heartening, yet confusing.

    “Nearly 80 percent of teachers, school staff, and childcare workers receive at least one shot of COVID-19 vaccine,” the release proclaims. These vaccinations include “more than 2 million” people in these professions who received doses through the federal retail pharmacy program and “5-6 million” vaccinated through state programs, all of whom received shots before the end of March.

    This CDC release is exciting because occupational data—or, figures tying vaccination counts to the jobs of those who got vaccinated—have been few and far between. As I wrote last month, state and local health departments have been unprepared to track this type of data; even getting states to report the race and ethnicity of their vaccinated residents has been a struggle.

    While you may need to be a teacher or fit another essential worker category in order to get vaccinated in your state, your provider may require you to show some proof of eligibility without recording that eligibility status anywhere. Meanwhile, school districts and local public health departments might be wary of surveying their local teachers to see who’s been vaccinated. Madeline Will explains the issue in EdWeek:

    Yet many vaccination sites do not collect or report occupation data, and many districts are not tracking vaccination rates themselves. Some district leaders say they’re wary of asking employees if they’ve gotten vaccinated because they don’t want to run afoul of any privacy laws, although the U.S. Equal Employment Opportunity Commission has said that employers can ask whether employees have gotten a COVID-19 vaccine.

    This brings us to the question: how did the CDC get its 80% figure? The agency’s press release is frustratingly unspecific; it’s all of 282 words long, with just one paragraph devoted to what a data journalist like myself would call the methodology, or the explanation of where the data come from.

    Here’s that explanation:

    CDC, in collaboration with the Administration for Children and Families, the Department of Education, and our non-federal partners, conducted surveys of Pre-K-12 teachers, school staff, and childcare workers at the end of March. CDC received almost 13,000 responses from education staff and nearly 40,000 responses from childcare workers. The responses closely matched available national race/ethnicity and demographic data on this specific workforce.

    Let’s unpack this. The CDC worked with two other federal agencies to conduct a survey of this high-priority occupation group, including 13,000 school staff and 40,000 childcare workers. The agency then extrapolated the results of this 53,000-person survey to estimate that 80% of Americans in these occupations have been vaccinated overall. While the CDC doesn’t provide any detail on how workers were chosen for the survey, the press release notes that responses match demographic data for this workforce, indicating that agency researchers did collect race, ethnicity, and other demographic information for those they surveyed.

    So, here’s my big question: is the CDC planning to release more detailed results from this survey? And if not… why?

    As we’ve noted in past CDD issues, teacher vaccination can go a long way towards inspiring confidence in school reopening programs, in school staff and parents alike. And that confidence is needed right now: February results of the Department of Education’s school COVID-19 survey, released last week, demonstrate that even though the majority of U.S. schools are now offering in-person instruction, only about one-third of students are learning in the classroom full-time. (More on those findings via AP’s Collin Binkley.)

    If the CDC released results of this vaccination survey for individual states and demographic groups, local public health and school district leadership may be able to see how their populations compare and respond accordingly. If, say, Texas is vaccinating fewer teachers than New York, Governor Greg Abbott can make a speech telling his state to step it up.

    And those states where a higher share of teachers have been vaccinated can use the information to inform school opening plans. The CDC’s press release doesn’t specify what share of that 80% vaccinated represents partially versus fully vaccinated school and childcare workers (which would also be useful data!), but even a workforce that was partially vaccinated at the end of March may be ready for in-person work by the end of April.

    All this is to say: show your work, CDC! Give us more detailed data!

    It’s also important to note, though, that while teachers are in the spotlight, they aren’t the only occupation for whom vaccination data should be a priority. Many staff in long-term care facilities have been unwilling to get vaccinated even though it would be a highly protective measure for the seniors they care for, Liz Essley Whyte wrote in late March at The Center for Public Integrity.

    The federal program that partnered with pharmacy chains to get LTC residents and staff vaccinated is now winding down, Whyte reports, even though some states still have a lot of LTC workers left who need shots. In seven states and D.C., less than a third of staff are vaccinated.

    Whyte writes:

    Low vaccination rates among staff at these facilities mean that workers continue to have greater risk of contracting COVID-19 themselves or passing the virus to their patients, including residents who can’t be inoculated for medical reasons. Low staff uptake can also complicate nursing homes’ attempt to reopen their doors to visitors like Caldwell, who are striving for some sense of normalcy.

    The Centers for Medicare & Medicaid Services are hoping to improve data on this issue. This agency proposed a new rule this week that would require nursing homes to tell the CDC how many of their health care workers are vaccinated against COVID-19, POLITICO reported on Friday. This rule would enable the CMS to identify specific facilities that are faring poorly and take appropriate action. And, if such data are made public, it would be easier for both reporters and families of nursing home residents to push for more LTC worker vaccinations.

    Still, privacy concerns continue to be a barrier for more detailed vaccination data of all types. Some of the big pharmacy chains that are administering huge shares of shots are requiring vaccine recipients to share their emails or phone numbers when they register for an appointment—then saving that data to use for future marketing. Getting patient contact information is an easy way to ensure people actually show up for their appointments, but when it’s a private company collecting your phone number instead of your public health department, it’s understandable that people might be a bit concerned about giving any information away.

    More detailed data standards, along with communication between governments and vaccine providers, could have saved the U.S. from the patchwork of vaccination data we’re now facing. But instead, here we are. Asking the CDC to please send out a longer press release. Maybe with a state-by-state data table included.

  • COVID source shout-out: New York expands eligibility

    COVID source shout-out: New York expands eligibility

    This week, New York Governor Andrew Cuomo announced two major expansions for vaccine eligibility. State residents age 30 and older became eligible starting on March 30, and residents age 16 and older became eligible starting on April 6.

    The announcement inspired a surge in “very online” people booking appointments, Twitter comedy, and speculation about what else we might be able to push the increasingly scandal-embroiled Governor Cuomo to do (legalize weed, apparently!).

    But most importantly, it allowed two of my favorite vaccine communicators to get their shots: Drew Armstrong, lead data wrangler for the Bloomberg Vaccine Tracker, and Huge Ma, computer engineer behind the TurboVax Twitter account, which shares available vaccine appointments in New York City.

    If you’d like to learn more about Bloomberg’s tracker, check out the recording and recap of our first Diving into COVID-19 data workshop, at which Armstrong was a featured speaker. And if you’d like to learn more about TurboVax, check out this recent (and rather horny) profile in The Cut. Ma has been using his platform to spread awareness about anti-Asian racism and raise money for Welcome to Chinatown, an initiative to support Chinatown businesses. It’s a pretty cool organization; I recommend checking it out and donating if you can, especially if you (like me) used the TurboVax account to find your vaccine appointment.

  • Pfizer for the whole pfamily

    Good news for people with kids: this week, Pfizer and BioNTech released results for their trial involving adolescents aged 12-15. In the trial, no participants who received the vaccine contracted symptomatic COVID-19 out of a total of 2,260 participants, marking an efficacy rate of 100%. (Remember in December the efficacy rate was 95% for adults.) 18 participants in the placebo group did get symptomatic COVID-19. Additionally, Dr. Fauci said in the April 2 White House COVID-19 briefing that, by the end of the year, there should be enough data to safely vaccinate children of any age. 

    The results are, obviously, fantastic. But there was a wrinkle in reporting said results; one that pointed to the dangers of communicating science via press release. Originally, as Dr. Natalie Dean pointed out on Twitter, there was some confusion over whether there were no cases in the vaccinated group at all, or whether there were just no symptomatic cases:

    This is pretty important as infections in this group tend to be asymptomatic. Apoorva Mandavilli, who broke the Pfizer story for the New York Times, clarified that she had been told that there were in fact no infections:

    Until someone pointed out that STAT had clarified that there were no symptomatic infections: 

    Mandavilli decided to triple check, and turns out:

    Basically, someone at Pfizer messed up and incorrectly said that there had been no infections in the vaccine group at all when they really meant that there were no symptomatic infections. It doesn’t look like they regularly tested participants who had gotten the vaccine vs participants who got the placebo. This sounds like splitting hairs, but precision matters when communicating the results of highly anticipated trials. “No infections” and “no symptomatic cases” are different results. It’s a blow to Pfizer’s credibility in their press releases, and it was probably at least really annoying for Mandavilli. 

    In the meantime, Johnson & Johnson has also begun a trial in adolescents, so hopefully whoever is running PR for them saw this Twitter thread (or is reading this article 👀) and will know to be more careful than the Pfizer guy was. 

    But for now, we can rejoice in what is still very promising data. You get a Pfizer! And you get a Pfizer! How about a Pfizer for the little one? EVERYBODY GETS A PFIZER! (Well, when it gets actually authorized for that age group.)

    Related posts

    • Sources and updates, November 12
      Sources and updates for the week of November 12 include new vaccination data, a rapid test receiving FDA approval, treatment guidelines, and more.
    • How is the CDC tracking the latest round of COVID-19 vaccines?
      Following the end of the federal public health emergency in May, the CDC has lost its authority to collect vaccination data from all state and local health agencies that keep immunization records. As a result, the CDC is no longer providing comprehensive vaccination numbers on its COVID-19 dashboards. But we still have some information about this year’s vaccination campaign, thanks to continued CDC efforts as well as reporting by other health agencies and research organizations.
    • Sources and updates, October 8
      Sources and updates for the week of October 8 include new papers about booster shot uptake, at-home tests, and Long COVID symptoms.
    • COVID source shout-out: Novavax’s booster is now available
      This week, the FDA authorized Novavax’s updated COVID-19 vaccine. Here’s why some people are excited to get Novavax’s vaccine this fall, as opposed to Pfizer’s or Moderna’s.
  • When the data journalist becomes a data point

    When the data journalist becomes a data point

    Last night, I received my first dose of the Moderna COVID-19 vaccine. I don’t usually publish more personal writing in the CDD, but it felt appropriate to share a short reflection I wrote during my 15-minute waiting period.

    I write this sitting in a back corner of the Science Skills High School gym, a couple of minutes after receiving my first dose of the Moderna vaccine.

    “I can’t take credit for it,” said the health professional who gave me the shot, with a voice that reminded me of my high school biology teacher.

    I believe she was referring to how easy the shot went in—in and out, the smoothest jab, I might not have felt it if I hadn’t been paying close attention, the goosebumps on my arms rising. I believe she was being specific. But I like to imagine she meant the whole thing—the gym, the people in scrubs and yellow vests, the red dots marking six-foot intervals on the floor, the vials. The vials, manufactured somewhere in New Hampshire or maybe Colorado, packed and stored below freezing and brought here. All the centuries of science and people that brought me here, to the gym, brought the shot to my arm. It went in smooth, but I felt the weight behind it.

    I thought about telling her, I’m a science reporter.  I’ve been on the COVID beat for a year. We are almost one year since my first COVID Tracking Project shift, my first time squinting at the numbers on dashboards and wondering if that ever might be me. But I didn’t say anything, let her deliver her form speech, her warnings about the side effects. “Your arm will be sore, maybe a light fever, take Tylenol,” she said. “Better than getting COVID, though!” I replied.

    Better to let me be just another data point, today. Another body moving through the pipeline. Another voice saying, thank you.

  • Stop me if you’ve heard this one: AstraZeneca is having vaccine issues

    Stop me if you’ve heard this one: AstraZeneca is having vaccine issues

    Remember when I said “we’ll see if anything else happens” in last week’s article on AstraZeneca’s issues? Well, I accept full responsibility for manifesting the chaos that happened earlier this week and I promise I won’t tempt fate again this time around. If you’re confused, as I certainly was, here’s just what the hell happened.

    On Monday, AstraZeneca released results from their Phase 3 trials in the United States, and they looked good: 79% efficacy against symptomatic disease, 100% efficacy against hospitalizations and deaths. This was certainly a welcome result for the company which is continuing to grapple with fallout from rare cases of blood clots that have been reported in some people after they got the vaccine, and gears started to turn to get EUA approval in the United States. (Even though, again, the U.S. just promised most of their supply to Canada and Mexico. Everyone wants FDA clout, I guess.)

    But on Tuesday, officials started to question the results. The results released on Monday had looked better than more recent results released elsewhere, one of which showed an overall efficacy of around 60%. Also, as Dr. Eric Topol pointed out, the data were fairly incomplete:

    Independent reviewers from the data and safety monitoring board sent “a harsh note” to AstraZeneca, according to Anthony Fauci, and sure enough, it soon became clear that AstraZeneca had released outdated (better) numbers instead of the real results from the trial, obfuscating how efficacious the vaccine actually was in the U.S. trial. 

    After all this, on Wednesday morning, AstraZeneca released the updated overall efficacy number: 76%. All that drama over docking three percentage points. (Though they did also complete the dataset, thus satisfying Dr. Topol and saving them more of his very pointed tweets. Thank you Dr. Topol.) 

    Dr. Ashish Jha sums it up pretty well:

    But Roxanne Khamsi sums it up even better:

    We’ll see if anything el—nope, I promised I wouldn’t.

    Related posts

    • Sources and updates, November 12
      Sources and updates for the week of November 12 include new vaccination data, a rapid test receiving FDA approval, treatment guidelines, and more.
    • How is the CDC tracking the latest round of COVID-19 vaccines?
      Following the end of the federal public health emergency in May, the CDC has lost its authority to collect vaccination data from all state and local health agencies that keep immunization records. As a result, the CDC is no longer providing comprehensive vaccination numbers on its COVID-19 dashboards. But we still have some information about this year’s vaccination campaign, thanks to continued CDC efforts as well as reporting by other health agencies and research organizations.
    • Sources and updates, October 8
      Sources and updates for the week of October 8 include new papers about booster shot uptake, at-home tests, and Long COVID symptoms.
    • COVID source shout-out: Novavax’s booster is now available
      This week, the FDA authorized Novavax’s updated COVID-19 vaccine. Here’s why some people are excited to get Novavax’s vaccine this fall, as opposed to Pfizer’s or Moderna’s.
  • What the hell is going on with the Oxford-AstraZeneca vaccine?

    What the hell is going on with the Oxford-AstraZeneca vaccine?

    The problem child of COVID-19 vaccines was back in the news this week. After South Africa suspended the Oxford-AstraZeneca vaccine’s use when it failed to slow the spread of the predominant B.1.351 variant, vaccination using this vaccine has been suspended and then resumed in many European countries following reports of blood clots in some people who received it. 

    According to a release from AstraZeneca, there have been 15 cases of deep vein thrombosis and 22 cases of pulmonary embolism in people who have gotten the vaccine, as of March 8. These are serious complications—seven of those people died. Countries that suspended the vaccine’s use include Spain, Italy, France, and Germany, among others. (Europe tends to act as more of a bloc than North America when it comes to vaccines. Consider: Canada has authorized use of the AstraZeneca vaccine while the US has literal fridges full of the stuff just sitting there waiting for approval.)

    Since the initial suspension, investigations have been launched and apparently concluded that there is no causative relationship between the vaccine and these symptoms. According to Emer Cooke, the executive director of the European Medicines Agency (EMA), in a press conference on March 18: “The committee… concluded that the vaccine is not associated with an increase in the overall risk of thromboembolic events or blood clots.”

    And, according to the WHO on March 17: “At this time, WHO considers that the benefits of the AstraZeneca vaccine outweigh its risks and recommends that vaccinations continue.” Europe has since started to resume vaccinating with the Oxford-AstraZeneca vaccine, starting with France, Germany, and Italy. (Except not in Finland, where they just suspended it again after two people got similar blood clots.)

    So all’s well that ends well right? Well, not necessarily. Besides that Finland wrinkle, some scientists and officials are concerned that this entire rigmarole could undermine public trust in the AstraZeneca vaccine. It’s worth noting that a tiny population experienced these effects out of the millions of people who have already gotten the vaccine. And blood clots are fairly common in the population; you’re going to expect some people to develop them just by sheer chance. But it’s also worth noting that these complications are serious, and rare among the age group that they were reported in. Not slowing down could have the same fear-inducing effect. As Shobita Parthasarathy says in her Slate column, “[T]his crisis isn’t about science at all. It’s about public trust, and scared citizens cannot be easily convinced by expertise that feels remote. Our solutions need to reflect that.”

    We’ll see if anything else happens. But in the meantime, the US has since promised to share its stockpile of the Oxford-AstraZeneca vaccine with Canada and Mexico, so it looks like it’s at least medium-steam ahead for now. 

    In summation:

    More vaccine posts

    • Sources and updates, November 12
      Sources and updates for the week of November 12 include new vaccination data, a rapid test receiving FDA approval, treatment guidelines, and more.
    • How is the CDC tracking the latest round of COVID-19 vaccines?
      Following the end of the federal public health emergency in May, the CDC has lost its authority to collect vaccination data from all state and local health agencies that keep immunization records. As a result, the CDC is no longer providing comprehensive vaccination numbers on its COVID-19 dashboards. But we still have some information about this year’s vaccination campaign, thanks to continued CDC efforts as well as reporting by other health agencies and research organizations.
    • Sources and updates, October 8
      Sources and updates for the week of October 8 include new papers about booster shot uptake, at-home tests, and Long COVID symptoms.
    • COVID source shout-out: Novavax’s booster is now available
      This week, the FDA authorized Novavax’s updated COVID-19 vaccine. Here’s why some people are excited to get Novavax’s vaccine this fall, as opposed to Pfizer’s or Moderna’s.